Mind Cure Health (CSE: MCUR) has completed the development of its first products. The company has completed the proprietary formulations for what it refers to as “all-natural integrated medicines intended to prepare and support patients of psychedelic therapies.”
The first two products, referred to as Mindful Preparation and Mindful Integration, are intended as pre and post-treatment supplements surrounding the use of psychedelic therapies. The supplements are now expected to be finalized in the current quarter, and made available to therapists and individuals in capsule and powder form in mid-2021.
The products mark Mind Cure’s first foray into products that are designed to be for psychedelic therapy support, a field in which the company intends to become the leader within. The products have been formulated to “encourage an effective healing experience and to balance the brain’s natural chemistry before and after psychedelic treatment.”
“Our mission as innovators within the psychedelic space is to identify areas of care where visionary thinking and leadership can be applied to transform and improve the experience of healing. First, we recognized the opportunity for psychedelic therapy and innovative digital therapeutics with iSTRYM, and now we’re helping to ensure the best, individualized support possible for people throughout their healing journey.”
Kelsey Ramsden, President & CEO of Mind Cure
Mind Cure Health last traded at $0.75 on the CSE.
Sponsored · Cambria Gold Mines
FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
